Jones v. Evonik Corporation

CourtDistrict Court, E.D. Louisiana
DecidedAugust 10, 2022
Docket2:22-cv-01522
StatusUnknown

This text of Jones v. Evonik Corporation (Jones v. Evonik Corporation) is published on Counsel Stack Legal Research, covering District Court, E.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Evonik Corporation, (E.D. La. 2022).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

GENEIVA JONES CIVIL ACTION

VERSUS No. 22-1522

EVONIK CORPORATION, ET AL. SECTION I

ORDER & REASONS Before the Court is defendant Shell Oil Company’s (“Shell”) Rule 12(b)(6) motion1 to dismiss. Also before the Court is defendant Evonik Corporation’s (“Evonik”) Rule 12(b)(6) motion2 to dismiss or, alternatively, Rule 12(e) motion for a more definite statement. Plaintiff Geneiva Jones (“plaintiff”) opposes3 both motions. For the reasons that follow, the Court will deny both motions. I. BACKGROUND A. Procedural History This case arises out of alleged exposure to ethylene oxide (“EtO”) near a petrochemical plant in Reserve, Louisiana (the “Facility”), owned and operated by Evonik and Shell.4 Shell owned and operated the Facility from 1991 until 1999,5 and Evonik has owned and operated the Facility since that time.6

1 R. Doc. No. 4 (motion); R. Doc. No. 11 (reply). 2 R. Doc. No. 12 (motion); R. Doc. No. 17 (reply). 3 R. Doc. Nos. 8, 14. 4 R. Doc. No. 2, at 1 ¶ 1. 5 Id. at 4 ¶ 16. 6 Id. at 4 ¶ 17. On April 26, 2021, fourteen plaintiffs filed an action in the Civil District Court for St. John the Baptist Parish, alleging that inhalation of EtO emitted from the Facility was a substantial factor in causing plaintiffs’ cancer, or their spouses’

cancer.7 On June 4, 2021, Evonik removed the case to federal court, contending that the Court has diversity jurisdiction under 28 U.S.C. § 1332.8 The action was allotted to Section R. On May 27, 2022, Judge Vance issued an Order and Reasons granting Shell’s motion to dismiss in its entirety, on the grounds of prescription and the non- applicability of contra non valentem. Ellis v. Evonik Corp., No. 21-1089, --- F. Supp.

3d ---, 2022 WL 1719196, at *8 (E.D. La. May 27, 2022) (Vance, J.). Judge Vance dismissed these claims as to Shell without prejudice, and she granted plaintiffs leave to amend their complaint to plead facts, specific to each plaintiff, to support the application of contra non valentem after their dates of diagnoses. Id. Judge Vance also granted in part and denied in part Evonik’s motion to dismiss. Specifically, Judge Vance dismissed plaintiff’s battery claims with prejudice. Id. at *16. Judge Vance denied the motion with respect to plaintiffs’ continuing-tort claims under Louisiana's

vicinage articles. Id. Judge Vance dismissed plaintiffs’ negligence claim without prejudice, granting plaintiffs leave to amend as to that claim. Id. Finally, Judge Vance, noting the significant factual variations between plaintiffs as to the nature and duration of their exposure and their types of cancer,

7 R. Doc. No. 1-2. 8 Id. concluded that a severance was warranted. Id. at *14. Plaintiff Jones’ action was allotted to Section I, and plaintiff thereafter filed her amended complaint.9

B. Factual Background The facts, as alleged in plaintiff’s amended complaint, are as follows. EtO is an odorless, colorless gas used to make a range of products, including antifreeze, textiles, plastics, detergents and adhesives.10 EtO is one of 187 pollutants that EPA has classified as “hazardous air pollutants” or “air toxics.”11 “Scientific and industry studies show that long-term exposure to EtO increases the risk of cancers of the white blood cells[ ] including, but not limited to, non-Hodgkin lymphoma, myeloma,

lymphocytic leukemia, and breast cancer.”12 The World Health Organization and various federal agencies have classified EtO as a carcinogen.13 The Facility has emitted large volumes of EtO gas for several decades.14 The EtO emitted by the Facility remains in the air for months, becomes concentrated in atmospheric inversions, and moves through neighboring communities through prevailing winds.15 Because its half-life in the atmosphere is 211 days, EtO remains

in the air near the Facility long after it has been emitted.16

9 R. Doc. No. 2. 10 R. Doc. No. 2, at 4 ¶ 18, 5 ¶ 20. 11 Id. at 5 ¶ 21. 12 Id. at 5 ¶ 22. 13 Id. at 6 ¶¶ 26–35. 14 Id. at 2 ¶ 36. 15 Id. at 2 ¶ 37. 16 Id. The Facility releases state-authorized amounts of EtO into the atmosphere, which are nevertheless dangerous to persons working and living near the Facility, as set forth in greater detail below.17 The Facility also releases unauthorized amounts

of EtO into the air and water.18 Such unauthorized releases are called “fugitive releases,” and they are caused by undetected and unrepaired leaks and faulty equipment, among other things.19 Fugitive EtO emissions from the Facility have dramatically increased the volume of EtO in the atmosphere around the Facility and in the surrounding community, “including just by way of example, multiple unauthorized releases of EtO in 2012 and 2013 that may have led to as much as 1950

lbs. of EtO being released into the atmosphere according to the facility, which is approximately the same amount of planned emissions that were released those years such that the fugitive emissions doubled the amount of EtO in the air.”20 In August 2018, the Environmental Protection Agency (“EPA”) released the results of the 2014 National Air Toxics Assessment (“2014 NATA”).21 The 2014 NATA estimated concentrations of airborne toxins and population exposure, and it calculated the associated risks of cancer and other serious health problems.22 The

assessment revealed that individuals living in census tracts around the Facility,

17 Id. at 2 ¶ 40. 18 Id. 19 Id. 20 Id. 21 R. Doc. No. 1-2, at 9. 22 R. Doc. No. 1-2, at 9. including plaintiff, have some of the highest risks of cancer from EtO exposure in the country.23 The 2014 NATA results were not communicated to any lay persons and the

citizens of St. John the Baptist Parish.24 The EPA Office of Inspector General (“OIG”) issued a management alert in March 2020 that called on the EPA and state and local officials to provide information about EtO to impacted residents who faced increased and “unacceptable” risks of cancer from certain facilities’ EtO emissions, specifically including the Evonik Facility.25 The 2020 OIG alert called on the EPA to conduct risk assessments of the identified facilities, including Evonik’s, and to develop new

emissions standards for facilities emitting EtO that are creating unreasonable risks for surrounding communities.26 The EPA’s assessment confirmed that individuals living near the Evonik Facility have a risk of developing cancer that is eight times what the EPA considers to be “acceptable.”27 Despite the OIG’s 2020 alert, there was no public awareness initiative or campaign by the defendants or any government agency to educate the community until 2021, when the first public outreach meeting was organized by the EPA to

inform local residents they face an increased risk of developing cancer from Evonik’s EtO emissions.28 At that meeting, the EPA explained that, notwithstanding the fact

23 Id. 24 R. Doc. No. 2, at 8 ¶ 41. 25 Id. 26 Id. 27 Id. 28 Id. that Evonik has decreased its EtO emissions from 2014 to 2020 by nearly 50%, the levels emitted were still not “sufficiently protective of human health” according to EPA guidelines and standards, even though they were within permitted limits,

pursuant to state law.29 With respect to Evonik’s claimed reduction in levels of EtO emissions from 2014 to 2020, the decrease in EtO emitted into the ambient air was mostly attributable to the Facility reducing “fugitive” EtO emissions, i.e., unplanned emissions caused by leaks in equipment, faulty processes, and accidents.30 According to the EPA, Evonik was able to reduce unplanned fugitive emissions by 92% from

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Spivey v. Robertson
197 F.3d 772 (Fifth Circuit, 1999)
Collins v. Morgan Stanley Dean Witter
224 F.3d 496 (Fifth Circuit, 2000)
Terrebonne Parish School Board v. Mobil Oil Corp.
310 F.3d 870 (Fifth Circuit, 2002)
Plotkin v. IP Axess Inc.
407 F.3d 690 (Fifth Circuit, 2005)
Cuvillier v. Taylor
503 F.3d 397 (Fifth Circuit, 2007)
Cutrer v. McMillan
308 F. App'x 819 (Fifth Circuit, 2009)
Kling Realty Co., Inc. v. Chevron USA, Inc.
575 F.3d 510 (Fifth Circuit, 2009)
Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Gentilello v. Rege
627 F.3d 540 (Fifth Circuit, 2010)
James Clark v. Amoco Production Co., Etc.
794 F.2d 967 (Fifth Circuit, 1986)
Campo v. Correa
828 So. 2d 502 (Supreme Court of Louisiana, 2002)
Joseph v. Dickerson
754 So. 2d 912 (Supreme Court of Louisiana, 2000)
Rando v. Anco Insulations Inc.
16 So. 3d 1065 (Supreme Court of Louisiana, 2009)
Boykin v. Louisiana Transit Co., Inc.
707 So. 2d 1225 (Supreme Court of Louisiana, 1998)
Cole v. Celotex Corp.
620 So. 2d 1154 (Supreme Court of Louisiana, 1993)
McCray v. New England Ins. Co.
579 So. 2d 1156 (Louisiana Court of Appeal, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Jones v. Evonik Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-evonik-corporation-laed-2022.